These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 36352098)

  • 41. Systemic sclerosis: Recent insight in clinical management.
    Zanatta E; Codullo V; Avouac J; Allanore Y
    Joint Bone Spine; 2020 Jul; 87(4):293-299. PubMed ID: 31568838
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis.
    Fuschiotti P; Larregina AT; Ho J; Feghali-Bostwick C; Medsger TA
    Arthritis Rheum; 2013 Jan; 65(1):236-46. PubMed ID: 23001877
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of IL-13 in systemic sclerosis.
    Fuschiotti P
    Cytokine; 2011 Dec; 56(3):544-9. PubMed ID: 21920770
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13.
    Aliprantis AO; Wang J; Fathman JW; Lemaire R; Dorfman DM; Lafyatis R; Glimcher LH
    Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2827-30. PubMed ID: 17307869
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The pathogenesis of systemic sclerosis.
    Katsumoto TR; Whitfield ML; Connolly MK
    Annu Rev Pathol; 2011; 6():509-37. PubMed ID: 21090968
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis.
    Kania G; Rudnik M; Distler O
    Nat Rev Rheumatol; 2019 May; 15(5):288-302. PubMed ID: 30953037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High reactive oxygen species in fibrotic and nonfibrotic skin of patients with diffuse cutaneous systemic sclerosis.
    Bourji K; Meyer A; Chatelus E; Pincemail J; Pigatto E; Defraigne JO; Singh F; Charlier C; Geny B; Gottenberg JE; Punzi L; Cozzi F; Sibilia J
    Free Radic Biol Med; 2015 Oct; 87():282-9. PubMed ID: 26143738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of skin fibrosis in systemic sclerosis.
    Jinnin M
    J Dermatol; 2010 Jan; 37(1):11-25. PubMed ID: 20175837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
    Yanaba K
    J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells.
    Melissaropoulos K; Iliopoulos G; Sakkas LI; Daoussis D
    Front Immunol; 2022; 13():925741. PubMed ID: 35812378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis.
    Cabral-Marques O; Riemekasten G
    Autoimmun Rev; 2016 Jul; 15(7):690-4. PubMed ID: 26970493
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach.
    Corriveau MP; Boufaied I; Lessard J; Chabaud S; Senécal JL; Grodzicky T; Chartier S; Raymond Y; Moulin VJ
    J Pathol; 2009 Mar; 217(4):534-42. PubMed ID: 19086038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cellular Transdifferentiation: A Crucial Mechanism of Fibrosis in Systemic Sclerosis.
    Jimenez SA; Piera-Velazquez S
    Curr Rheumatol Rev; 2024; 20(4):388-404. PubMed ID: 37921216
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
    Jimenez SA; Piera-Velazquez S
    Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Spleen elastography in patients with Systemic sclerosis.
    Karalilova R; Doykova K; Batalov Z; Doykov D; Batalov A
    Rheumatol Int; 2021 Mar; 41(3):633-641. PubMed ID: 33495915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
    Zhao M; Wu J; Wu H; Sawalha AH; Lu Q
    Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of cellular senescence in the pathogenesis of systemic sclerosis.
    Tsou PS; Shi B; Varga J
    Curr Opin Rheumatol; 2022 Nov; 34(6):343-350. PubMed ID: 35979691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis.
    Del Galdo F; Sotgia F; de Almeida CJ; Jasmin JF; Musick M; Lisanti MP; Jiménez SA
    Arthritis Rheum; 2008 Sep; 58(9):2854-65. PubMed ID: 18759267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
    Hasegawa M; Takehara K
    Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sparing effect of hemiplegia on skin fibrosis and microvascular involvement: reports of two cases of systemic sclerosis and review of the literature.
    Ughi N; Hervey SA; Gualtierotti R; Silvana Z; Herrick AL; Ingegnoli F; Meroni P
    Semin Arthritis Rheum; 2015 Apr; 44(5):597-601. PubMed ID: 25488380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.